CLL	Chronic lymphocytic leukemia
CIT	Chemoimmunotherapy
BR	Bendamustine and rituximab
BTKi	Bruton’s tyrosine kinase inhibitor
BCL2i	B-cell lymphoma 2 inhibitor
MRD	Measurable residual disease
BH3	B-cell lymphoma 2 homology 3
BAX	B-cell lymphoma 2-associated X proteins
BAK	B-cell lymphoma 2 antagonist/killer
BIM	B-cell lymphoma 2-interacting mediator
uMRD	Undetectable measurable residual disease
AML	Acute myeloid leukemia
BTK	Bruton’s tyrosine kinase
cBTKi	Covalent Bruton’s tyrosine kinase inhibitor
ncBTKi	Non-covalent Bruton’s tyrosine kinase inhibitor
R/R	Relapsed/refractory
PFS	Progression-free survival
OS	Overall survival
XLA	X-linked agammaglobulinemia
IGH	Immunoglobulin heavy chain
IVO	Ibrutinib, venetoclax, and abinutuzumab
AVO	Acalabrutinib, venetoclax, and obinutuzumab
PVO	Pirtobrutinib, venetoclax, and obinutuzumab
BM	Bone marrow
PB	Peripheral blood
PROTAC	Proteolysis-targeting chimera
POI	Protein of interest
VHL	Von Hippel–Lindau
CRBN	Cereblon
FC	Flow cytometry
IgH-PCR	Immunoglobulin heavy-chain polymerase chain reaction
NGS	Next-generation sequencing
ASO	Allele-specific oligonucleotide